Company Filing History:
1 out of 147 
1 out of 528 
Years Active: 2019
Title: Daisuke Tokita: Innovator in Antibody Development
Introduction
Daisuke Tokita is a prominent inventor based in Kobe, Japan. He is recognized for his contributions to the field of biotechnology, particularly in the development of antibodies. His innovative work has led to significant advancements in medical research and therapeutic applications.
Latest Patents
Daisuke Tokita holds a patent for an anti-MYL9 antibody. This invention provides an anti-Myl9 antibody or a Myl9 binding fragment that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans. The patent also includes a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody with binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of this antibody was identified. Consequently, a humanized antibody incorporating the CDR sequence of the mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.
Career Highlights
Throughout his career, Daisuke Tokita has worked with notable institutions, including Chiba University and Eisai R&D Management Co., Ltd. His work has been instrumental in advancing the understanding of antibody interactions and their potential therapeutic uses.
Collaborations
Daisuke has collaborated with esteemed colleagues such as Toshinori Nakayama and Motoko Kimura. Their combined expertise has contributed to the success of various research projects and innovations in the field.
Conclusion
Daisuke Tokita's contributions to antibody development exemplify the impact of innovative research in biotechnology. His work continues to influence the medical field and offers promising avenues for future therapeutic advancements.